ANTXR1

Summary

ANTXR1 (ANTXR cell adhesion molecule 1, HGNC:21014) is a protein-coding gene on chromosome 2p13.3, encoding Anthrax toxin receptor 1 (Q9H6X2). Plays a role in cell attachment and migration. It is a common-essential gene (DepMap: required in 97.4% of cancer cell lines).

This gene encodes a type I transmembrane protein and is a tumor-specific endothelial marker that has been implicated in colorectal cancer. The encoded protein has been shown to also be a docking protein or receptor for Bacillus anthracis toxin, the causative agent of the disease, anthrax. The binding of the protective antigen (PA) component, of the tripartite anthrax toxin, to this receptor protein mediates delivery of toxin components to the cytosol of cells. Once inside the cell, the other two components of anthrax toxin, edema factor (EF) and lethal factor (LF) disrupt normal cellular processes. Three alternatively spliced variants that encode different protein isoforms have been described.

Source: NCBI Gene 84168 — RefSeq curated summary.

At a glance

• Gene–disease (curated): GAPO syndrome (Definitive, ClinGen) — +6 more curated relationships
• GWAS associations: 39
• Clinical variants (ClinVar): 4,402 total — 98 pathogenic, 52 likely-pathogenic
• Phenotypes (HPO): 102
• Cancer driver (intOGen): loss-of-function (tumor-suppressor-like) across 4 cancer types
• Cancer dependency (DepMap): dependent in 97.4% of screened cell lines (common-essential)
• Dosage sensitivity (ClinGen): haploinsufficiency little evidence, triplosensitivity no evidence
• MANE Select transcript: NM_032208

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21014
Approved symbol	ANTXR1
Name	ANTXR cell adhesion molecule 1
Location	2p13.3
Locus type	gene with protein product
Status	Approved
Aliases	TEM8, FLJ21776, FLJ10601, ATR
Ensembl gene	ENSG00000169604
Ensembl biotype	protein_coding
OMIM	606410
Entrez	84168

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 8 protein_coding, 3 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000303714, ENST00000409349, ENST00000409829, ENST00000463335, ENST00000481119, ENST00000482235, ENST00000497197, ENST00000679548, ENST00000681059, ENST00000681568, ENST00000681816, ENST00000894109

RefSeq mRNA: 4 — MANE Select: NM_032208 NM_001410840, NM_018153, NM_032208, NM_053034

CCDS: CCDS1892, CCDS46313, CCDS46314, CCDS92773

Canonical transcript exons

ENST00000303714 — 18 exons

Exon	Start	End
ENSE00001130052	69245225	69249327
ENSE00001164648	69193335	69193415
ENSE00001164655	69182493	69182660
ENSE00001164661	69181786	69181881
ENSE00001190737	69124565	69124643
ENSE00001360156	69152169	69152264
ENSE00001360162	69102842	69102940
ENSE00001360193	69123017	69123086
ENSE00001434518	69170248	69170289
ENSE00001920255	69013179	69013651
ENSE00003504437	69077408	69077488
ENSE00003576810	69071754	69071787
ENSE00003579443	69090859	69090919
ENSE00003598462	69073022	69073101
ENSE00003611927	69075590	69075658
ENSE00003648213	69070647	69070728
ENSE00003656385	69040044	69040115
ENSE00003665749	69044742	69044813

Expression profiles

Bgee: expression breadth ubiquitous, 270 present calls, max score 99.54.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.1293 / max 866.6649, expressed in 1356 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
20741	13.5011	1075
20743	9.7883	1279
20745	2.9893	606
20744	2.9493	1063
20742	0.9014	402

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
stromal cell of endometrium	CL:0002255	99.54	gold quality
decidua	UBERON:0002450	99.41	gold quality
palpebral conjunctiva	UBERON:0001812	99.35	gold quality
saphenous vein	UBERON:0007318	99.23	gold quality
vena cava	UBERON:0004087	99.06	gold quality
tendon of biceps brachii	UBERON:0008188	99.02	gold quality
right coronary artery	UBERON:0001625	98.99	gold quality
synovial joint	UBERON:0002217	98.77	gold quality
pericardium	UBERON:0002407	98.65	gold quality
urethra	UBERON:0000057	98.54	gold quality
thoracic aorta	UBERON:0001515	98.45	gold quality
ascending aorta	UBERON:0001496	98.44	gold quality
descending thoracic aorta	UBERON:0002345	98.27	gold quality
mammalian vulva	UBERON:0000997	98.24	gold quality
skin of hip	UBERON:0001554	98.23	gold quality
germinal epithelium of ovary	UBERON:0001304	98.21	gold quality
tibia	UBERON:0000979	98.15	gold quality
aorta	UBERON:0000947	98.09	gold quality
coronary artery	UBERON:0001621	98.07	gold quality
gall bladder	UBERON:0002110	98.00	gold quality
left coronary artery	UBERON:0001626	97.92	gold quality
mammary duct	UBERON:0001765	97.91	gold quality
artery	UBERON:0001637	97.84	gold quality
popliteal artery	UBERON:0002250	97.81	gold quality
tibial artery	UBERON:0007610	97.81	gold quality
visceral pleura	UBERON:0002401	97.80	gold quality
calcaneal tendon	UBERON:0003701	97.74	gold quality
trigeminal ganglion	UBERON:0001675	97.56	gold quality
superficial temporal artery	UBERON:0001614	97.37	gold quality
tendon	UBERON:0000043	97.34	gold quality

Single-cell (SCXA)

Detected in 8 experiment(s), a significant marker in 6.

Experiment	Marker?	Max mean expression
E-GEOD-135922	yes	54.53
E-MTAB-8410	yes	41.62
E-ANND-3	yes	19.68
E-CURD-119	yes	9.74
E-GEOD-83139	yes	6.63
E-ENAD-27	yes	6.55
E-GEOD-124858	no	429.83
E-MTAB-10290	no	204.13

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): TP53

miRNA regulators (miRDB)

203 targeting ANTXR1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-3134	100.00	66.43	777
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-518D-5P	100.00	67.51	979
HSA-MIR-518E-5P	100.00	67.66	954
HSA-MIR-518F-5P	100.00	67.51	979
HSA-MIR-519A-5P	100.00	67.66	954
HSA-MIR-519B-5P	100.00	67.66	954
HSA-MIR-519C-5P	100.00	67.66	954
HSA-MIR-520C-5P	100.00	67.51	979
HSA-MIR-522-5P	100.00	67.66	954
HSA-MIR-523-5P	100.00	67.66	954
HSA-MIR-526A-5P	100.00	67.51	979
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-19A-3P	99.98	75.33	2762
HSA-MIR-19B-3P	99.98	75.44	2754
HSA-MIR-548AN	99.97	70.91	2817
HSA-MIR-6793-5P	99.97	65.95	758

Functional genomics

ClinGen dosage: haploinsufficiency 1 (little evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map DepMap (CRISPR cell-line fitness): dependent in 97.4% of screened cell lines, common-essential.

Literature-anchored findings (GeneRIF, showing 40)

• Here we describe the cloning of the human PA receptor using a genetic complementation approach (PMID:11700562)
• ATR/TEM8 protein is highly expressed in epithelial cells, which represent the primary location for bacterial invasion. (PMID:15689409)
• This is the first demonstration that the ATR/TEM8 protein is highly expressed in epithelial cells, suggesting that the ATR/TEM8 expression pattern is highly relevant for understanding the pathogenesis of anthrax infection. (PMID:15689409)
• results indicate that TEM8 plays a positive role in endothelial cell activities related to angiogenesis (PMID:15777794)
• These results suggest that the TEM-8 vW and transmembrane domains may play an important biological role in TEM-8 related tubule formation. (PMID:15993844)
• because protective antigen binds to CMG2 with much higher affinity than it does to TEM8, a lower pH is needed to attenuate CMG2 binding to allow pore formation; toxin can form pores at different points in the endocytic pathway (PMID:16141341)
• Data show that cells expressing palmitoylation-defective mutant receptors are less sensitive to anthrax toxin due to a lower number of surface receptors as well as premature internalization of protective antigen without a requirement for heptamerization. (PMID:16401723)
• TEM8 is a new adhesion molecule linking collagen I or PA to the actin cytoskeleton (PMID:16762926)
• TEM8 expression levels in DC-based therapeutic vaccines would allow the selection of a subgroup of patients who are most likely to benefit from therapeutic vaccination. (PMID:19440709)
• ANTXR1 does not use an adaptor to bind the cytoskeleton. This peptide orders actin filaments into arrays, demonstrating an actin bundling activity that is novel for a membrane protein (PMID:19817382)
• actin was also found to be essential for efficient heptamerization of anthrax toxin PA, but only when bound to one of its 2 receptors, TEM8 (PMID:20221438)
• the crystal structure of the TEM8 extracellular vWA domain at 1.7 A resolution. (PMID:20585457)
• Data show that the two different PA oligomers are equally stabilized by ANTXR interactions. (PMID:21079738)
• studies reveal that TEM8 exists in different forms at the cell surface, a structure dependent on interactions with components of the actin cytoskeleton (PMID:21129411)
• Results describe the expression, purification and crystallization of human anthrax toxin receptor 1 vWA domain to 1.8 A resolution from a single crystal. (PMID:21206026)
• The copy number of CEA and TEM-8 mRNA, as detected by a real-time quantitative PCR, appears to be a promising marker for evaluating the risk of tumor spread. (PMID:21573768)
• postulate that the developmentally controlled expression of TEM8 modulates endothelial cell response to canonical Wnt signaling to regulate vessel patterning and density (PMID:21829615)
• TEM8 was expressed at a higher level in the stroma adjacent to the triple-negative breast cancer in all cases, with focal immunoreactive areas within the tumor. (PMID:21965755)
• TEM8.1 expression in breast cancer cells confers a more aggressive, proangiogenic phenotype. (PMID:22085271)
• An acidic region in the cytosolic tail of ANTXR1 decreases actin association, sending a signal that prevents binding of ANTXR1 to the protective antigen and providing evidence that cytoskeletal dynamics regulate ANTXR1 function. (PMID:22303962)
• Disruption of Tem8 results in impaired growth of human tumor xenografts of diverse origin including melanoma, breast, colon, and lung cancer. (PMID:22340594)
• Two new splice variants, one encoding a membrane-bound form of the receptor and the other secreted, which we have designated V4 and V5 (the latter being the only variant expressed in the prostate). (PMID:22912819)
• Mutations affecting ANTXR1 function are responsible for GAPO syndrome’s characteristic generalized defect in extracellular-matrix homeostasis. (PMID:23602711)
• There is an attenuation of ANTXR1 expression post-infection which may be a protective mechanism that has evolved to prevent reinfection. (PMID:23607659)
• High ANTXR1 accelerates breast tumor growth and lung metastasis. (PMID:23832666)
• ANTXR2 is expressed by human uterine smooth muscle cell and appears important for normal human uterine smooth muscle cell viability, migration and contractility. (PMID:24060446)
• TEM8-targeted siRNAs also offered significant protection against lethal toxin in human macrophage-like cells. (PMID:24742682)
• These studies expand the allelic spectrum in this rare condition and potentially provide insight into the role of ANTXR1 in the regulation of the extracellular matrix. (PMID:25045128)
• In the absence of any N-linked glycans, TEM8 fails to fold correctly and is recognized by the ER quality control machinery. (PMID:25781883)
• TEM8 may be differentially expressed between wound types and loss of this molecule impacts HaCaT growth and migration, potentially implicating this molecule as a factor involved in successful progression of wound healing. (PMID:26677171)
• Findings suggest that down-regulation of tumor endothelial marker 8 play an important role in the inhibition of tumorigenesis and development of osteosarcoma. (PMID:26996335)
• expression does not affect cytotoxicity to anthrax toxin (PMID:27170489)
• Consistent with experimental study, computational results indicate the metal ion in TEM8 contributes significantly to the binding affinity, and anthrax protective antigen-TEM8 binding is more favorable in the presence of Mg(2+) than Ca(2+) . (PMID:28437008)
• These studies identify ANTXR1, a class of receptor that is shared by a mammalian virus and a bacterial toxin, as the cellular receptor for Seneca Valley virus. (PMID:28650343)
• Novel targets ANTXR1 and RSPO2 were confirmed to be suppressed by miR-493 directly. (PMID:28651234)
• Silencing TEM8 may inhibit proliferation of XWLC05 lung cancer cells, promote cell apoptosis, arrest the cell cycle at G1 phase and decrease the migration and invasive ability. (PMID:29115620)
• Our findings implicate ANTXR1 as a candidate gene for isolated TA, suggest the involvement of specific hypomorphic alleles, and expand the previously known ANTXR1-associated phenotypes. (PMID:29436111)
• The frequency of the CC genotype of rs4527238 was observed to be high in the low HbF patient group compared to the high HbF group. (PMID:30114697)
• TEM8 is a novel receptor for uPA (PMID:30241478)
• inspection showed that MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the probable targets of CAR T cell therapy in gastric adenocarcinoma. (PMID:30260046)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	antxr1a	ENSDARG00000025672
danio_rerio	antxr1b	ENSDARG00000074075
mus_musculus	Antxr1	ENSMUSG00000033420
rattus_norvegicus	Antxr1	ENSRNOG00000008678

Paralogs (2): ANTXR2 (ENSG00000163297), ANTXRL (ENSG00000274209)

Protein

Protein identifiers

Anthrax toxin receptor 1 — Q9H6X2 (reviewed: Q9H6X2)

Alternative names: Tumor endothelial marker 8

All UniProt accessions (4): A0A7P0T9B0, A0A7P0Z463, Q9H6X2, H0YC24

UniProt curated annotations — full annotation on UniProt →

Function. Plays a role in cell attachment and migration. Interacts with extracellular matrix proteins and with the actin cytoskeleton and thereby plays an important role in normal extracellular matrix (ECM) homeostasis. Mediates adhesion of cells to type 1 collagen and gelatin, reorganization of the actin cytoskeleton and promotes cell spreading. Plays a role in the angiogenic response of cultured umbilical vein endothelial cells. May also act as a receptor for PLAU. Upon ligand binding, stimulates the phosphorylation of EGFR and ERK1/2. (Microbial infection) Acts as a receptor for protective antigen (PA) of B.anthracis. (Microbial infection) Mediates cell entry of Seneca Valley virus (SVV) when glycosylated.

Subunit / interactions. Interacts with gelatin and type 1 collagen. Interacts with the actin cytoskeleton. (Microbial infection) Interacts (via VWFA domain) with the protective antigen (PA) of B.anthracis. Binding does not occur in the presence of calcium.

Subcellular location. Cell membrane. Cell projection. Lamellipodium membrane. Filopodium membrane.

Tissue specificity. Detected in umbilical vein endothelial cells (at protein level). Highly expressed in tumor endothelial cells.

Post-translational modifications. Glycosylated. Glycosylation is essential for Seneca Valley virus (SVV) attachment and entry. Phosphorylated upon PLAU binding.

Disease relevance. Hemangioma, capillary infantile (HCI) [MIM:602089] A condition characterized by dull red, firm, dome-shaped hemangiomas, sharply demarcated from surrounding skin, usually presenting at birth or occurring within the first two or three months of life. They result from highly proliferative, localized growth of capillary endothelium and generally undergo regression and involution without scarring. Disease susceptibility is associated with variants affecting the gene represented in this entry. GAPO syndrome (GAPOS) [MIM:230740] An autosomal recessive disease characterized by growth retardation, alopecia, failure of tooth eruption, and progressive optic atrophy in some patients. The disease is caused by variants affecting the gene represented in this entry.

Induction. Up-regulated in cultured angiogenic umbilical vein endothelial cells.

Miscellaneous. May be produced at very low levels due to a premature stop codon in the mRNA, leading to nonsense-mediated mRNA decay. Prostate-specific.

Similarity. Belongs to the ATR family.

Isoforms (6)

UniProt ID	Names	Canonical?
Q9H6X2-1	1	yes
Q9H6X2-2	2
Q9H6X2-3	3
Q9H6X2-4	4
Q9H6X2-5	5, V4
Q9H6X2-6	6, V5

RefSeq proteins (4): NP_001397769, NP_060623, NP_115584, NP_444262 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002035	VWF_A	Domain
IPR008399	Anthrax_toxin_rcpt_C	Domain
IPR008400	Anthrax_toxin_rcpt_extracel	Domain
IPR017360	Anthrax_toxin_rcpt	Family
IPR036465	vWFA_dom_sf	Homologous_superfamily

Pfam: PF00092, PF05586, PF05587

UniProt features (46 total): splice variant 9, helix 8, strand 6, region of interest 4, binding site 3, glycosylation site 3, compositionally biased region 2, topological domain 2, sequence variant 2, signal peptide 1, chain 1, modified residue 1, disulfide bond 1, transmembrane region 1, turn 1, domain 1

Structure

Experimental structures (PDB)

5 structures.

PDB	Method	Resolution (Å)
3N2N	X-RAY DIFFRACTION	1.8
6ADM	ELECTRON MICROSCOPY	2.84
6ADL	ELECTRON MICROSCOPY	3.08
6ADR	ELECTRON MICROSCOPY	3.38
6CX1	ELECTRON MICROSCOPY	3.8

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H6X2-F1	72.76	0.38

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 52; 54; 118

Post-translational modifications (1): 362

Disulfide bonds (1): 39–220

Glycosylation sites (3): 166, 184, 262

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-5210891	Uptake and function of anthrax toxins

MSigDB gene sets: 870 (showing top): PID_FANCONI_PATHWAY, GOBP_DNA_TEMPLATED_DNA_REPLICATION_MAINTENANCE_OF_FIDELITY, GOBP_REGULATION_OF_DOUBLE_STRAND_BREAK_REPAIR, GOBP_RNA_TEMPLATED_DNA_BIOSYNTHETIC_PROCESS, GOBP_CHROMOSOME_ORGANIZATION, RODRIGUES_THYROID_CARCINOMA_ANAPLASTIC_UP, FLECHNER_PBL_KIDNEY_TRANSPLANT_REJECTED_VS_OK_UP, GOBP_RESPONSE_TO_IONIZING_RADIATION, GOBP_POSITIVE_REGULATION_OF_DNA_DAMAGE_RESPONSE_SIGNAL_TRANSDUCTION_BY_P53_CLASS_MEDIATOR, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_POSITIVE_REGULATION_OF_DNA_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_ERBB_SIGNALING_PATHWAY, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_UP, REACTOME_MEIOTIC_SYNAPSIS, GOBP_CELLULAR_RESPONSE_TO_UV

GO Biological Process (6): blood vessel development (GO:0001568), actin cytoskeleton organization (GO:0030036), substrate adhesion-dependent cell spreading (GO:0034446), positive regulation of epidermal growth factor receptor signaling pathway (GO:0045742), negative regulation of extracellular matrix assembly (GO:1901202), epidermal growth factor receptor signaling pathway (GO:0007173)

GO Molecular Function (6): transmembrane signaling receptor activity (GO:0004888), collagen binding (GO:0005518), signaling receptor activity (GO:0038023), metal ion binding (GO:0046872), actin filament binding (GO:0051015), protein binding (GO:0005515)

GO Cellular Component (8): plasma membrane (GO:0005886), external side of plasma membrane (GO:0009897), cell surface (GO:0009986), endosome membrane (GO:0010008), lamellipodium membrane (GO:0031258), filopodium membrane (GO:0031527), membrane (GO:0016020), cell projection (GO:0042995)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Uptake and actions of bacterial toxins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein-containing complex binding	2
cell projection membrane	2
vasculature development	1
anatomical structure development	1
cytoskeleton organization	1
actin filament-based process	1
cell-substrate adhesion	1
epidermal growth factor receptor signaling pathway	1
regulation of epidermal growth factor receptor signaling pathway	1
positive regulation of ERBB signaling pathway	1
extracellular matrix assembly	1
regulation of extracellular matrix assembly	1
negative regulation of extracellular matrix organization	1
ERBB signaling pathway	1
signaling receptor activity	1
molecular transducer activity	1
cation binding	1
actin binding	1
binding	1
membrane	1
cell periphery	1
plasma membrane	1
cell surface	1
side of membrane	1
endosome	1
cytoplasmic vesicle membrane	1
bounding membrane of organelle	1
lamellipodium	1
leading edge membrane	1
filopodium	1

Protein interactions and networks

STRING

1758 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ANTXR1	LRP6	O75581	814
ANTXR1	VWF	P04275	809
ANTXR1	KDR	P35968	745
ANTXR1	FURIN	P09958	741
ANTXR1	DUSP5	Q16690	557
ANTXR1	DKK2	Q9UBU2	547
ANTXR1	FZD1	Q9UP38	546
ANTXR1	PLXDC1	Q8IUK5	544
ANTXR1	FLT1	P16057	537
ANTXR1	PI4K2A	Q9BTU6	516
ANTXR1	CD248	Q9HCU0	507
ANTXR1	SOST	Q9BQB4	496
ANTXR1	PTH1R	Q03431	490
ANTXR1	LRP5	O75197	475
ANTXR1	OR8J1	Q8NGP2	470

IntAct

68 interactions, top by confidence:

A	B	Type	Score
LMO1	ZBTB43	psi-mi:“MI:0914”(association)	0.830
PRMT2	SAMD1	psi-mi:“MI:0914”(association)	0.640
STX12	SNAP23	psi-mi:“MI:0914”(association)	0.640
ANTXR1	POTEF	psi-mi:“MI:0914”(association)	0.530
IL13RA2	METTL15	psi-mi:“MI:0914”(association)	0.530
FCGRT	GOLIM4	psi-mi:“MI:0914”(association)	0.530
SPACA1	GOLIM4	psi-mi:“MI:0914”(association)	0.530
OCLN	DNAJC13	psi-mi:“MI:0914”(association)	0.530
TNFSF8	LGALS8	psi-mi:“MI:0914”(association)	0.530
SPSB2	ARHGEF10	psi-mi:“MI:0914”(association)	0.530
ANTXR1	WFS1	psi-mi:“MI:0914”(association)	0.530
ANTXR1	PCOLCE	psi-mi:“MI:0407”(direct interaction)	0.440
LRP6	ANTXR1	psi-mi:“MI:0915”(physical association)	0.400
Ppp1cb	MYO1C	psi-mi:“MI:0914”(association)	0.350
Bsdc1	SSB	psi-mi:“MI:0914”(association)	0.350
GJB2	SNX3	psi-mi:“MI:0914”(association)	0.350
MYO19	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
KLF8		psi-mi:“MI:0914”(association)	0.350
SYN1	LUC7L3	psi-mi:“MI:0914”(association)	0.350
FLNA	PLEKHG3	psi-mi:“MI:0914”(association)	0.350
Sidt2	PRSS1	psi-mi:“MI:0914”(association)	0.350
Tecpr2	PUF60	psi-mi:“MI:0914”(association)	0.350
MYH9	NAP1L1	psi-mi:“MI:0914”(association)	0.350
MYH9	PLEKHG3	psi-mi:“MI:0914”(association)	0.350

BioGRID (213): ANTXR1 (Affinity Capture-MS), TUBB3 (Affinity Capture-MS), RSAD1 (Affinity Capture-MS), CA11 (Affinity Capture-MS), ZNF146 (Affinity Capture-MS), POTEF (Affinity Capture-MS), TUBB8 (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), KANK2 (Affinity Capture-MS), RICTOR (Affinity Capture-MS), LRP11 (Affinity Capture-MS), PDIA5 (Affinity Capture-MS), TUBA4A (Affinity Capture-MS), TUBA1A (Affinity Capture-MS), PC (Affinity Capture-MS)

ESM2 similar proteins: A1XQX1, A1XQX3, A1XQY0, A8WGA3, C6K2K4, D0PRN2, D0PRN4, D4A1J9, E9PUN2, O13097, O42596, O73612, O73874, P0DI97, P52795, P52796, P58400, P58401, P98172, Q01974, Q0PMD2, Q17QD6, Q28142, Q28143, Q460M5, Q63373, Q63376, Q6NW40, Q6PCX7, Q6PFE7, Q7TQ33, Q80TG9, Q8BNJ6, Q8BXA0, Q8C985, Q8IYR6, Q8NC67, Q91590, Q96B86, Q96NI6

Diamond homologs: A6NF34, P58335, Q0PMD2, Q4R7B7, Q6DFX2, Q8BVM2, Q9CZ52, Q9H6X2

SIGNOR signaling

0 interactions.

Disease & clinical

Cancer significance

From intOGen — cancer-driver classification: loss-of-function (tumor-suppressor-like) across 4 cancer types — LUNG, MEL, STAD, UTUC.

Clinical variants and AI predictions

ClinVar

4402 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	98
Likely pathogenic	52
Uncertain significance	2294
Likely benign	1591
Benign	161

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1069016	NM_001184.4(ATR):c.5851C>T (p.Arg1951Ter)	Pathogenic
1072254	NM_001184.4(ATR):c.4915_4918dup (p.Thr1640fs)	Pathogenic
1072974	NC_000003.11:g.(?142272059)(142275427_?)del	Pathogenic
1076365	NM_001184.4(ATR):c.529C>T (p.Arg177Ter)	Pathogenic
1076685	NM_001184.4(ATR):c.5563del (p.His1855fs)	Pathogenic
1076770	NM_001184.4(ATR):c.3402dup (p.Asn1135Ter)	Pathogenic
1357123	NC_000003.12:g.142536202del	Pathogenic
1372183	NM_001184.4(ATR):c.6836dup (p.Asn2279fs)	Pathogenic
1376891	NM_001184.4(ATR):c.5656C>T (p.Arg1886Ter)	Pathogenic
1378337	NM_001184.4(ATR):c.5786_5787insCTAGAAAG (p.Arg1929delinsSerTer)	Pathogenic
1417890	NM_001184.4(ATR):c.5870_5877dup (p.Ala1960fs)	Pathogenic
1421134	NM_001184.4(ATR):c.3567_3568dup (p.Glu1190fs)	Pathogenic
1423201	NM_001184.4(ATR):c.4896dup (p.Leu1633fs)	Pathogenic
1423837	NM_001184.4(ATR):c.2593_2594dup (p.Leu865_Lys866insTer)	Pathogenic
1434427	NM_001184.4(ATR):c.5218dup (p.Val1740fs)	Pathogenic
1444557	NM_001184.4(ATR):c.392T>A (p.Leu131Ter)	Pathogenic
1452399	NM_001184.4(ATR):c.6022C>T (p.Arg2008Ter)	Pathogenic
1453489	NM_001184.4(ATR):c.5679del (p.Tyr1894fs)	Pathogenic
1453747	NM_001184.4(ATR):c.3856C>T (p.Gln1286Ter)	Pathogenic
1454309	NM_001184.4(ATR):c.1885dup (p.Ser629fs)	Pathogenic
1458489	NM_001184.4(ATR):c.7550_7553dup (p.Asn2518delinsLysTer)	Pathogenic
156536	NM_001184.4(ATR):c.3477G>T (p.Met1159Ile)	Pathogenic
1897758	NM_001184.4(ATR):c.1953G>A (p.Trp651Ter)	Pathogenic
1906193	NM_001184.4(ATR):c.5029C>T (p.Gln1677Ter)	Pathogenic
1970626	NM_001184.4(ATR):c.5863dup (p.Leu1955fs)	Pathogenic
2007236	NM_001184.4(ATR):c.4912C>T (p.Gln1638Ter)	Pathogenic
2022356	NM_001184.4(ATR):c.2137C>T (p.Gln713Ter)	Pathogenic
2039249	NM_001184.4(ATR):c.1492C>T (p.Gln498Ter)	Pathogenic
2043590	NM_001184.4(ATR):c.6463G>T (p.Glu2155Ter)	Pathogenic
2044496	NM_001184.4(ATR):c.4507C>T (p.Arg1503Ter)	Pathogenic

SpliceAI

10456 predictions. Top by Δscore:

Variant	Effect	Δscore
2:69013652:G:GG	donor_gain	1.0000
2:69038925:A:T	donor_gain	1.0000
2:69040042:A:AG	acceptor_gain	1.0000
2:69040043:G:GG	acceptor_gain	1.0000
2:69044740:A:AG	acceptor_gain	1.0000
2:69044740:A:AT	acceptor_loss	1.0000
2:69044741:G:GA	acceptor_gain	1.0000
2:69044741:G:GT	acceptor_loss	1.0000
2:69044815:T:G	donor_loss	1.0000
2:69070645:A:AG	acceptor_gain	1.0000
2:69070646:G:GG	acceptor_gain	1.0000
2:69070646:GA:G	acceptor_gain	1.0000
2:69077397:T:A	acceptor_gain	1.0000
2:69089501:GAAA:G	donor_gain	1.0000
2:69090916:GGAG:G	donor_gain	1.0000
2:69090917:GAGG:G	donor_gain	1.0000
2:69102835:A:AG	acceptor_gain	1.0000
2:69102836:TTTCA:T	acceptor_loss	1.0000
2:69102837:TTCA:T	acceptor_loss	1.0000
2:69102838:TCA:T	acceptor_loss	1.0000
2:69102839:CAG:C	acceptor_gain	1.0000
2:69102840:A:AG	acceptor_gain	1.0000
2:69102840:AGA:A	acceptor_gain	1.0000
2:69102841:G:C	acceptor_gain	1.0000
2:69102841:G:GC	acceptor_gain	1.0000
2:69102841:GA:G	acceptor_gain	1.0000
2:69102841:GAGT:G	acceptor_gain	1.0000
2:69102841:GAGTC:G	acceptor_gain	1.0000
2:69102937:CTCA:C	donor_gain	1.0000
2:69102941:G:GG	donor_gain	1.0000

AlphaMissense

3669 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:69013614:T:C	C39R	1.000
2:69013616:C:G	C39W	1.000
2:69013633:T:C	L45P	1.000
2:69013647:G:C	D50H	1.000
2:69013648:A:C	D50A	1.000
2:69013648:A:T	D50V	1.000
2:69040066:T:A	W59R	1.000
2:69040066:T:C	W59R	1.000
2:69040068:G:C	W59C	1.000
2:69040068:G:T	W59C	1.000
2:69044758:T:C	S81P	1.000
2:69044770:T:C	F85L	1.000
2:69044772:C:A	F85L	1.000
2:69044772:C:G	F85L	1.000
2:69070676:T:C	L109P	1.000
2:69070717:G:A	G123R	1.000
2:69070717:G:C	G123R	1.000
2:69070718:G:A	G123E	1.000
2:69073049:C:A	A147D	1.000
2:69073052:T:C	L148S	1.000
2:69073058:A:T	D150V	1.000
2:69073059:T:A	D150E	1.000
2:69073059:T:G	D150E	1.000
2:69073061:G:A	G151E	1.000
2:69073061:G:T	G151V	1.000
2:69075626:T:C	C177R	1.000
2:69075627:G:A	C177Y	1.000
2:69075628:T:G	C177W	1.000
2:69075630:T:A	V178D	1.000
2:69075632:G:C	G179R	1.000

dbSNP variants (sampled 300 via entrez): RS1000008474 (2:69166000 T>C), RS1000017952 (2:69084725 G>A,T), RS1000090163 (2:69213088 T>G), RS1000123026 (2:69059174 A>G), RS1000130170 (2:69089333 C>T), RS1000147298 (2:69149072 T>C), RS1000149572 (2:69207540 G>C,T), RS1000152992 (2:69077756 C>T), RS1000164337 (2:69233288 C>A), RS1000181165 (2:69222851 C>A), RS1000199133 (2:69171740 A>G), RS1000205696 (2:69056094 A>G), RS1000205949 (2:69090749 A>G), RS1000237211 (2:69177273 A>G), RS1000237862 (2:69059470 C>T)

Disease associations

OMIM: gene MIM:606410 | disease phenotypes: MIM:210600, MIM:614564, MIM:230740, MIM:600057, MIM:602089, MIM:114480, MIM:122470

GenCC curated gene-disease

Disease	Classification	Inheritance
GAPO syndrome	Definitive	Autosomal recessive
Seckel syndrome 1	Definitive	Autosomal recessive
sarcoma	Moderate	Autosomal dominant
familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome	Moderate	Autosomal dominant
Seckel syndrome	Supportive	Autosomal recessive
capillary infantile hemangioma	Limited	Autosomal dominant
familial prostate carcinoma	Limited	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
GAPO syndrome	Definitive	AR

Mondo (15): Seckel syndrome 1 (MONDO:0008869), familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome (MONDO:0013806), GAPO syndrome (MONDO:0009263), hereditary neoplastic syndrome (MONDO:0015356), bladder exstrophy-epispadias-cloacal exstrophy complex (MONDO:0700039), capillary infantile hemangioma (MONDO:0011191), hereditary breast carcinoma (MONDO:0016419), Cornelia de Lange syndrome 1 (MONDO:0007387), hereditary breast ovarian cancer syndrome (MONDO:0003582), ATR-X-related syndrome (MONDO:0016980), Seckel syndrome (MONDO:0019342), breast cancer (MONDO:0007254), microcephaly (MONDO:0001149), familial prostate carcinoma (MONDO:0023122), sarcoma (MONDO:0005089)

Orphanet (12): Familial cutaneous telangiectasia and oropharyngeal cancer predisposition syndrome (Orphanet:313846), Seckel syndrome (Orphanet:808), GAPO syndrome (Orphanet:2067), Inherited cancer-predisposing syndrome (Orphanet:140162), Classic bladder exstrophy (Orphanet:93930), Hereditary breast cancer (Orphanet:227535), Cornelia de Lange syndrome (Orphanet:199), Hereditary breast and/or ovarian cancer syndrome (Orphanet:145), Microcephalic primordial dwarfism (Orphanet:324761), NON RARE IN EUROPE: Infantile capillary hemangioma (Orphanet:464293), OBSOLETE: Familial capillary hemangioma (Orphanet:91415), OBSOLETE: ATR-X-related syndrome (Orphanet:263355)

HPO phenotypes

102 total (30 of 102 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000007	Autosomal recessive inheritance
HP:0000135	Hypogonadism
HP:0000141	Amenorrhea
HP:0000174	Abnormal palate morphology
HP:0000179	Thick lower lip vermilion
HP:0000232	Everted lower lip vermilion
HP:0000260	Wide anterior fontanel
HP:0000274	Small face
HP:0000286	Epicanthus
HP:0000303	Mandibular prognathia
HP:0000316	Hypertelorism
HP:0000336	Prominent supraorbital ridges
HP:0000337	Broad forehead
HP:0000343	Long philtrum
HP:0000347	Micrognathia
HP:0000348	High forehead
HP:0000365	Hearing impairment
HP:0000369	Low-set ears
HP:0000411	Protruding ear
HP:0000453	Choanal atresia
HP:0000463	Anteverted nares
HP:0000485	Megalocornea
HP:0000486	Strabismus
HP:0000501	Glaucoma
HP:0000505	Visual impairment
HP:0000545	Myopia
HP:0000563	Keratoconus
HP:0000565	Esotropia
HP:0000586	Shallow orbits

GWAS associations

39 associations (top):

Study	Trait	p-value
GCST001263_23	Height	1.000000e-08
GCST004601_47	Red blood cell count	9.000000e-25
GCST004619_131	Reticulocyte fraction of red cells	3.000000e-09
GCST004622_165	Reticulocyte count	7.000000e-16
GCST005170_39	Intraocular pressure	2.000000e-13
GCST005580_240	Intraocular pressure	9.000000e-17
GCST005580_65	Intraocular pressure	5.000000e-12
GCST005993_70	Mean corpuscular hemoglobin	1.000000e-35
GCST005996_57	Red blood cell count	5.000000e-09
GCST006011_101	Mean corpuscular volume	2.000000e-44
GCST006394_46	Intraocular pressure	3.000000e-11
GCST006395_6	Glaucoma	2.000000e-06
GCST006412_24	Intraocular pressure	7.000000e-13
GCST006804_192	Red cell distribution width	3.000000e-08
GCST007600_69	Alzheimer’s disease	4.000000e-06
GCST008839_187	Height	9.000000e-09
GCST008839_416	Height	3.000000e-10
GCST009725_42	Intraocular pressure	2.000000e-11
GCST012245_5	Periodontitis (stage III/IV grade C)	3.000000e-06
GCST012365_3	Orofacial cleft x maternal periconceptional multivitamin use interaction (1df)	1.000000e-06
GCST90000025_751	Appendicular lean mass	3.000000e-09
GCST90002381_190	Eosinophil count	6.000000e-10
GCST90002386_563	High light scatter reticulocyte percentage of red cells	5.000000e-18
GCST90002390_169	Mean corpuscular hemoglobin	3.000000e-19
GCST90002390_170	Mean corpuscular hemoglobin	2.000000e-10
GCST90002390_171	Mean corpuscular hemoglobin	2.000000e-56
GCST90002392_315	Mean corpuscular volume	9.000000e-26
GCST90002392_316	Mean corpuscular volume	8.000000e-11
GCST90002392_317	Mean corpuscular volume	6.000000e-69
GCST90002396_254	Mean reticulocyte volume	8.000000e-19

EFO canonical traits (10, from GWAS)

EFO ID	Trait name
EFO:0004305	erythrocyte count
EFO:0007986	reticulocyte count
EFO:0004695	intraocular pressure measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0009188	Red cell distribution width
EFO:0009116	vitamin supplement exposure measurement
EFO:0004980	appendicular lean mass
EFO:0004842	eosinophil count
EFO:0010701	mean reticulocyte volume
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (7)

Descriptor	Name	Tree numbers
D061325	Hereditary Breast and Ovarian Cancer Syndrome	C04.588.180.483; C04.588.322.455.431; C04.700.517; C12.050.351.500.056.630.705.431; C12.050.351.937.418.685.431; C12.100.250.056.630.705.431; C12.900.418.685.431; C16.320.700.517; C17.800.090.500.483; C19.344.410.431; C19.391.630.705.431
D008831	Microcephaly	C05.660.207.620; C10.500.507.400.500; C16.131.621.207.620; C16.131.666.507.400.500
D009386	Neoplastic Syndromes, Hereditary	C04.700; C16.320.700
D012509	Sarcoma	C04.557.450.795
C562840	Breast Cancer, Familial (supp.)
C535642	Growth retardation, Alopecia, Pseudoanodontia and Optic atrophy (supp.)
C535860	Hemangioma, capillary infantile (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

82 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Estradiol	affects cotreatment, increases expression	4
methylmercuric chloride	affects cotreatment, increases expression	3
bisphenol A	affects expression, affects cotreatment, increases methylation, decreases expression	3
trichostatin A	affects cotreatment, increases expression	3
Tetrachlorodibenzodioxin	decreases expression	3
Tretinoin	increases expression, decreases expression	3
sodium arsenite	decreases expression, increases abundance	2
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
Air Pollutants	increases abundance, increases expression, decreases expression, affects cotreatment	2
Arsenic	increases abundance, affects methylation, decreases expression	2
Benzo(a)pyrene	decreases expression, increases methylation	2
Phenylmercuric Acetate	increases expression, affects cotreatment	2
Progesterone	affects cotreatment, increases expression	2
Rotenone	decreases expression, increases expression	2
Tobacco Smoke Pollution	decreases expression, increases expression	2
Valproic Acid	increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression, increases expression	2
Cadmium Chloride	decreases expression, increases abundance, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	increases phosphorylation	1
alpha-pinene	affects cotreatment, increases expression, increases abundance	1
propionaldehyde	increases expression	1
terbufos	increases methylation	1
beta-lapachone	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cobaltous chloride	decreases expression	1
butyraldehyde	decreases expression	1
chloroquine diphosphate	increases expression	1

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1JK	Abcam HeLa ANTXR1 KO	Cancer cell line	Female
CVCL_SC63	HAP1 ANTXR1 (-) 1	Cancer cell line	Male
CVCL_SC64	HAP1 ANTXR1 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

598 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03144206	PHASE4	ACTIVE_NOT_RECRUITING	Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study
NCT03244020	PHASE4	ENROLLING_BY_INVITATION	LMWH vs Aspirin for VTE Prophylaxis in Orthopaedic Oncology
NCT04033081	PHASE4	ACTIVE_NOT_RECRUITING	Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®
NCT02562170	PHASE4	COMPLETED	Protexa® Versus TiLoopBra® in Immediate Breast Reconstruction- A Pilot Study
NCT00014638	PHASE4	COMPLETED	Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
NCT00022386	PHASE4	COMPLETED	Epoetin Alfa in Treating Chemotherapy-Related Anemia in Women With Stage I, Stage II, or Stage III Breast Cancer
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00030758	PHASE4	UNKNOWN	Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
NCT00082277	PHASE4	COMPLETED	Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
NCT00087620	PHASE4	TERMINATED	A Study of Capecitabine In Combination With Docetaxel vs Capecitabine Followed by Docetaxel As First-Line Treatment For Metastatic Breast Cancer
NCT00121836	PHASE4	COMPLETED	A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
NCT00126360	PHASE4	UNKNOWN	STARS Breast Trial (Study of Anastrozole and Radiotherapy Sequencing Pilot)
NCT00127933	PHASE4	COMPLETED	XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer
NCT00128297	PHASE4	COMPLETED	Pamidronate Administration in Breast Cancer Patients With Bone Metastases
NCT00129597	PHASE4	UNKNOWN	Effect of Ketalar to Prevent Postoperative Chronic Pain After Mastectomy
NCT00131170	PHASE4	COMPLETED	Paravertebral Block for Breast Surgery
NCT00156039	PHASE4	COMPLETED	Randomized Trial of Follow-up Strategies in Breast Cancer
NCT00160901	PHASE4	COMPLETED	Complementary Therapies for the Reduction of Side Effects During Chemotherapy for Breast Cancer
NCT00171847	PHASE4	TERMINATED	Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients With Metastatic Breast Cancer
NCT00176046	PHASE4	COMPLETED	Mistletoe Extract in Early or Advanced Breast Cancer, A Feasibility Study
NCT00190697	PHASE4	COMPLETED	A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
NCT00234195	PHASE4	COMPLETED	Wellbutrin XL, Major Depressive Disorder and Breast Cancer
NCT00237133	PHASE4	COMPLETED	Treatment of Locally Advanced Breast Cancer With Letrozole in Postmenopausal Women
NCT00237224	PHASE4	COMPLETED	Open Label Study of Postmenopausal Women With ER and /or PgR Positive Breast Cancer Treated With Letrozole
NCT00241046	PHASE4	TERMINATED	Letrozole in the Treatment of 1st and 2nd Line Hormone Receptor Positive Breast Cancer: Pre-therapeutic Risk Assessment
NCT00277160	PHASE4	COMPLETED	A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer
NCT00323479	PHASE4	COMPLETED	Arthralgia During Anastrozole Therapy for Breast Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00356148	PHASE4	COMPLETED	The Efficacy of Prophylactic Antibiotic Administration During Breast Cancer Surgery in Overweight Patients.
NCT00372476	PHASE4	COMPLETED	Efficacy and Safety of Imatinib and Vinorelbine in Patients With Advanced Breast Cancer
NCT00413491	PHASE4	UNKNOWN	National Screening in Denmark With MR Versus Mammography and Ultrasound of Women With BRCA1 or BRCA2 Mutations
NCT00484614	PHASE4	UNKNOWN	Study the Role of Positron Emission Mammography in Pre-surgical Planning for Breast Cancer
NCT00485953	PHASE4	COMPLETED	Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor Therapy
NCT00496678	PHASE4	COMPLETED	Trial of Patient Navigation-Activation
NCT00531973	PHASE4	UNKNOWN	A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging
NCT00537771	PHASE4	COMPLETED	Liver Safety Under Upfront Arimidex vs Tamoxifen
NCT00544986	PHASE4	COMPLETED	A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer
NCT00613275	PHASE4	COMPLETED	Patient Navigation in the Safety Net:CONNECTeDD
NCT00638599	PHASE4	COMPLETED	Comparison of Laryngeal Mask Airway (LMA®) and Tracheal Tube in Modified Radical Mastectomy on Breast Cancer
NCT00647075	PHASE4	UNKNOWN	Yunzhi as Dietary Supplement in Breast Cancer